Table 6.
Base case analysis results.
Absolute | Incremental | Absolute | Incremental | |||||
---|---|---|---|---|---|---|---|---|
PER 8 mg/day | LCM 400 mg/day | Change% | PER 4 mg/day | LCM 200 mg/day | Change% | |||
Seizures | 467 | 608 | −141 | −23.22 | 717 | 789 | −72 | −9.14 |
LYs | 4.940 | 4.879 | 0.061 | 1.26 | 5.17 | 5.158 | 0.012 | 0.24 |
QALYs | 3.137 | 3.083 | 0.054 | 1.75 | 3.278 | 3.268 | 0.010 | 0.31 |
Drug costs | 9,144 | 11,462 | −23,18 | −20.22 | 7,304 | 8,229 | −925 | −11.24 |
Medical costs | 7,001 | 7,073 | −72 | −1.01 | 7,400 | 7,335 | 65 | 0.89 |
Total costs | 16,145 | 18,535 | −2,390 | −12.89 | 14,704 | 15,564 | −860 | −5.52 |
PER, perampanel; LCM, lacosamide; LY, life year; QALY, quality-adjusted life years.